Chimeric receives US patent covering CLTX CAR technology
Filed with ASX · · 2 pages · English
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Transformative Portfolio Expansion Presentation
- CLTX CAR T data shows regional control of tumour recurrence
- CLTX CAR t presents positive initial phase 1 clinical data
- First milestone on path to CDH17 CAR t clinical trial
- European patent granted for CLTX technology used in CHM 1101
Later from Chimeric Therapeutics
- Sponsored Research Agreement with University of Pennsylvania
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
- Entitlement Offer to raise approximately $18.1 million
- Successful completion of Institutional Entitlement Offer
- Chimeric partners with Be the Match BioTherapies
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics